NEWEST TO THE MARKET (FDA Drug Approvals)

Polivy (polatuzumab vedotin-piiq) – To treat adult patients with relapsed or refractory diffuse large B-cell lymphoma

Approval Date: 10 June 2019

—————————————————————————————————————————————————————————————————————————————

Piqray (alpelisib) – To treat breast cancer

Approval Date: 24 May 2019

Vyndaqel (tafamidis meglumine) – To treat heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults.

Approval Date: 3 May 2019

Skyrizi (risankizumab-rzaa) – To treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Approval Date: 23 Apr 2019

Balversa (erdafitinib) – To treat adult patients with locally advanced or metastatic bladder cancer.

Approval Date: 12 Apr 2019

Evenity (romosozumab-aqqg) – To treat osteoporosis in postmenopausal women at high risk of fracture.

Approval Date: 9 Apr 2019

Mayzent (siponimod) – To treat adults with relapsing forms of multiple sclerosis.

Approval Date: 26 Mar 2019

Sunosi (solriamfetol) – To treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.

Approval Date: 20 Mar 2019

Zulresso (brexanolone) – To treat postpartum depression (PPD) in adult women.

Approval Date: 19 Mar 2019

Egaten (triclabendazole)- To treat fascioliasis, a parasitic infestation caused by two species of flatworms or trematodes that mainly the affect the liver, sometimes referred to as “liver flukes”.

Approval Date: 13 Feb 2019

Cablivi (caplacizumab-yhdp) – To treat adult patients with acquired thrombotic thrombocytopenic purpura (aTTP).

Approval Date: 6 Feb 2019

Jeuveau (prabotulinumtoxinA-xvfs) – For the temporary improvement in the appearance of moderate to severe glabellar lines associated with levit8ed corrugator and/or procerus muscle activity in adult patients.

Approval Date: 1 Feb 2019

NEWEST TO THE MARKET (FDA Drug Approvals)

Polivy (polatuzumab vedotin-piiq) – To treat adult patients with relapsed or refractory diffuse large B-cell lymphoma

Piqray (alpelisib) – To treat breast cancer

Vyndaqel (tafamidis meglumine) – To treat heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults.

Skyrizi (risankizumab-rzaa) – To treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Balversa (erdafitinib) – To treat adult patients with locally advanced or metastatic bladder cancer.

Evenity (romosozumab-aqqg) – To treat osteoporosis in postmenopausal women at high risk of fracture.

Mayzent (siponimod) – To treat adults with relapsing forms of multiple sclerosis.

Sunosi (solriamfetol) – To treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.

Zulresso (brexanolone) – To treat postpartum depression (PPD) in adult women.

Egaten (triclabendazole)- To treat fascioliasis, a parasitic infestation caused by two species of flatworms or trematodes that mainly the affect the liver, sometimes referred to as “liver flukes”.

Cablivi (caplacizumab-yhdp) – To treat adult patients with acquired thrombotic thrombocytopenic purpura (aTTP).

Jeuveau (prabotulinumtoxinA-xvfs) – For the temporary improvement in the appearance of moderate to severe glabellar lines associated with levit8ed corrugator and/or procerus muscle activity in adult patients.

Food and Drug Administration (FDA)

NEWEST TO THE MARKET (FDA Drug Approvals)

Polivy (polatuzumab vedotin-piiq) – To treat adult patients with relapsed or refractory diffuse large B-cell lymphoma

Piqray (alpelisib) – To treat breast cancer

Vyndaqel (tafamidis meglumine) – To treat heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults.

Skyrizi (risankizumab-rzaa) – To treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Balversa (erdafitinib) – To treat adult patients with locally advanced or metastatic bladder cancer.

Evenity (romosozumab-aqqg) – To treat osteoporosis in postmenopausal women at high risk of fracture.

Mayzent (siponimod) – To treat adults with relapsing forms of multiple sclerosis.

Sunosi (solriamfetol) – To treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.

Zulresso (brexanolone) – To treat postpartum depression (PPD) in adult women.

Egaten (triclabendazole)- To treat fascioliasis, a parasitic infestation caused by two species of flatworms or trematodes that mainly the affect the liver, sometimes referred to as “liver flukes”.

Cablivi (caplacizumab-yhdp) – To treat adult patients with acquired thrombotic thrombocytopenic purpura (aTTP).

Jeuveau (prabotulinumtoxinA-xvfs) – For the temporary improvement in the appearance of moderate to severe glabellar lines associated with levit8ed corrugator and/or procerus muscle activity in adult patients.